Baricitinib
Code | Size | Price |
---|
TAR-T2485-2mg | 2mg | £102.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2485-5mg | 5mg | £117.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2485-1mL | 1 mL * 10 mM (in DMSO) | £123.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2485-10mg | 10mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2485-25mg | 25mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2485-50mg | 50mg | £166.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2485-100mg | 100mg | £189.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.
CAS:
1187594-09-7
Formula:
C16H17N7O2S
Molecular Weight:
371.42
Pathway:
Stem Cells; Tyrosine Kinase/Adaptors; JAK/STAT signaling; Chromatin/Epigenetic; Angiogenesis; Cell Cycle/Checkpoint
Purity:
0.9979
SMILES:
CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1[nH]cnc2nccc12
Target:
Tyrosine Kinases; JAK; Chk
References
1. Fridman JS, et al. J Immunol, 2010, 184(9), 5298-5307.
2. Kontzias A, et al. Curr Opin Pharmacol, 2012, 12(4), 464-470.
3. Norman P, et al. Expert Opin Ther Pat, 2012, 22(10), 1233-1249.
4. Norman P, et al. Expert Opin Ther Pat, 2012, 22(9), 1105-1109.
5. Kvacskay P, Yao N, Schnotz J H, et al. Increase of aerobic glycolysis mediated by activated T helper cells drives synovial fibroblasts towards an inflammatory phenotype: new targets for therapy?[J]. Arthritis Research & Therapy. 2021, 23(1): 1-15.